We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01792479
Recruitment Status : Completed
First Posted : February 15, 2013
Last Update Posted : April 15, 2016
Information provided by (Responsible Party):
BIND Therapeutics

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : April 2016
  Study Completion Date : April 2016